Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) EBT Margin: 2009-2024

Historic EBT Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -3.40%.

  • Anika Therapeutics' EBT Margin fell 914.00% to -8.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.06%, marking a year-over-year decrease of 3607.00%. This contributed to the annual value of -3.40% for FY2024, which is 601.00% down from last year.
  • As of FY2024, Anika Therapeutics' EBT Margin stood at -3.40%, which was down 230.17% from 2.61% recorded in FY2023.
  • Anika Therapeutics' 5-year EBT Margin high stood at 3.80% for FY2022, and its period low was -21.94% during FY2020.
  • For the 3-year period, Anika Therapeutics' EBT Margin averaged around 1.00%, with its median value being 2.61% (2023).
  • Per our database at Business Quant, Anika Therapeutics' EBT Margin slumped by 5,536bps in 2020 and then spiked by 2,529bps in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' EBT Margin stood at -21.94% in 2020, then soared by 2,529bps to 3.35% in 2021, then skyrocketed by 45bps to 3.80% in 2022, then crashed by 119bps to 2.61% in 2023, then crashed by 601bps to -3.40% in 2024.